26
total announcements
544578.BO · 15 min delayed
Rubicon Research Ltd
Rubicon Research Ltd has published its Business Responsibility and Sustainability Report for the financial year 2025-26, as required by SEBI regulations.
Rubicon Research Ltd
Rubicon Research Ltd has announced the notice of its 27th Annual General Meeting (AGM) along with the Integrated Annual Report for the financial year 2025-26. The AGM will be held on August 26, 2026, through video conferencing. The report is available on the company's website and will be sent to eligible members via email.
Rubicon Research Ltd
Rubicon Research Ltd has published a newspaper advertisement intimating shareholders about the 27th Annual General Meeting to be held through video conferencing, final dividend, and record date.
Rubicon Research Ltd
Rubicon Research Ltd has recommended a final dividend of Rs. 1.50 per Equity Share for the financial year ended March 31, 2026, subject to the approval of the shareholders at the ensuing 27th Annual General Meeting. The dividend, if approved, shall be paid to those shareholders whose names appear in the Register of Members of the Company or whose names appear as beneficial owners in the records of the Depositories as at the close of business hours on Friday, August 7, 2026. The Company is required to deduct tax at source (TDS) at the applicable rates while making the dividend payment.
Rubicon Research Ltd
Rubicon Research Ltd has filed a scheme of merger of its wholly owned subsidiary, Kia Health Tech Private Ltd, with the company, subject to regulatory approvals and stakeholder consent.
Rubicon Research Ltd
Rubicon Research Ltd, a pharmaceutical company, has acquired a manufacturing facility in East Brunswick, New Jersey, USA from InvaTech Pharma Solutions, LLC for an enterprise value of USD 2.9 million. The facility will focus on Rubicon's specialty and high-value products as well as demand from US government departments. Manufacturing is expected to commence in calendar year 2027.